AZTA · Azenta, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $18.5M | Q3 FY2026 | — |
| Adjusted EBITDA - Continuing Operations non-GAAP | $18M | Q3 FY2026 | — |
|
|
|||
| Adjusted EBITDA Margin - Continuing Operations non-GAAP | 11.4% | Q3 FY2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 46.2% | Q3 FY2026 | — |
|
|
|||
| Adjusted operating expense non-GAAP | $70M | Q3 FY2026 | — |
|
|
|||
| Adjusted operating income non-GAAP | $4.7M | Q3 FY2026 | — |
|
|
|||
| Adjusted operating margin non-GAAP | 2.9% | Q3 FY2026 | — |
|
|
|||
| Non-GAAP Diluted EPS Continuing Operations non-GAAP | $0.16 | Q3 FY2026 | — |
|
|
|||
| Capital expenditures | $6M | Q1 FY2026 | — |
| Free cash flow non-GAAP | $15M | Q1 FY2026 | — |
| Operating cash flow | $21M | Q1 FY2026 | — |
| Total balance of cash, cash equivalents, restricted cash and marketable securities | $571M | Q1 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AZTA
this stock
Azenta, Inc.
|
$1.60B | +9.8% | +3.6% | — | 12.2% |
|
ISRG
Intuitive Surgical Inc
|
$140.51B | -33.9% | +20.5% | 45.7 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$51.11B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$44.58B | -22.4% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.25B | -7.5% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AZTA | +7.7% | +29.0% | +35.3% | +29.8% | +9.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +9.6% | +25.7% | +24.2% | +27.7% | -2.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.